Literature DB >> 16614127

Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial.

Raymond F Burk1, Brooke K Norsworthy, Kristina E Hill, Amy K Motley, Daniel W Byrne.   

Abstract

Intervention trials with different forms of selenium are under way to assess the effects of selenium supplements on the incidence of cancer and other diseases. Plasma selenium biomarkers respond to selenium administration and might be useful for assessing compliance and safety in these trials. The present study characterized the effects of selenium supplementation on plasma selenium biomarkers and urinary selenium excretion in selenium-replete subjects. Moderate (approximately 200 microg/d) to large (approximately 600 microg/d) selenium supplements in the forms sodium selenite, high-selenium yeast (yeast), and l-selenomethionine (selenomethionine) were administered. Subjects were randomized into 10 groups (placebo and three dose levels of each form of selenium). Plasma biomarkers (selenium concentration, selenoprotein P concentration, and glutathione peroxidase activity) were determined before supplementation and every 4 weeks for 16 weeks. Urinary selenium excretion was determined at 16 weeks. Supplementation with selenomethionine and yeast raised the plasma selenium concentration in a dose-dependent manner. Selenite did not. The increased selenium concentration correlated with the amount of selenomethionine administered. Neither glutathione peroxidase activity nor selenoprotein P concentration responded to selenium supplementation. Urinary selenium excretion was greater after selenomethionine than after selenite, with excretion after yeast being intermediate and not significantly different from either of the other two. We conclude that plasma selenium concentration is useful in monitoring compliance and safety of selenium supplementation as selenomethionine but not as selenite. Plasma selenium seems to reflect the selenomethionine content of yeast but not the other yeast selenium forms. As judged by urinary selenium excretion, selenium in the form of selenomethionine is better absorbed than selenite.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614127     DOI: 10.1158/1055-9965.EPI-05-0950

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  71 in total

Review 1.  Inherited defects of thyroid hormone metabolism.

Authors:  A M Dumitrescu; S Refetoff
Journal:  Ann Endocrinol (Paris)       Date:  2011-04-21       Impact factor: 2.478

Review 2.  Selenium, selenoproteins and the thyroid gland: interactions in health and disease.

Authors:  Lutz Schomburg
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  A human model of selenium that integrates metabolism from selenite and selenomethionine.

Authors:  Meryl E Wastney; Gerald F Combs; Wesley K Canfield; Philip R Taylor; Kristine Y Patterson; A David Hill; James E Moler; Blossom H Patterson
Journal:  J Nutr       Date:  2011-02-02       Impact factor: 4.798

4.  Minimising the population risk of micronutrient deficiency and over-consumption: a new approach using selenium as an example.

Authors:  Andrew G Renwick; Lars O Dragsted; Reg J Fletcher; Albert Flynn; John M Scott; Sandra Tuijtelaars; T Wildemann
Journal:  Eur J Nutr       Date:  2008-01-14       Impact factor: 5.614

Review 5.  Selenium at the redox interface of the genome, metabolome and exposome.

Authors:  Jolyn Fernandes; Xin Hu; M Ryan Smith; Young-Mi Go; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2018-06-05       Impact factor: 7.376

6.  Higher selenium status is associated with adverse blood lipid profile in British adults.

Authors:  Saverio Stranges; Martin Laclaustra; Chen Ji; Francesco P Cappuccio; Ana Navas-Acien; Jose M Ordovas; Margaret Rayman; Eliseo Guallar
Journal:  J Nutr       Date:  2009-11-11       Impact factor: 4.798

7.  Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial.

Authors:  John P Richie; Arun Das; Ana M Calcagnotto; Raghu Sinha; Wanda Neidig; Jiangang Liao; Eugene J Lengerich; Arthur Berg; Terryl J Hartman; Amy Ciccarella; Aaron Baker; Matthew G Kaag; Susan Goodin; Robert S DiPaola; Karam El-Bayoumy
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-17

8.  Serum selenium and prognosis in cardiovascular disease: results from the AtheroGene study.

Authors:  Edith Lubos; Christoph R Sinning; Renate B Schnabel; Philipp S Wild; Tanja Zeller; Hans J Rupprecht; Christoph Bickel; Karl J Lackner; Dirk Peetz; Joseph Loscalzo; Thomas Münzel; Stefan Blankenberg
Journal:  Atherosclerosis       Date:  2009-09-12       Impact factor: 5.162

9.  Selenium and mercury in the Brazilian Amazon: opposing influences on age-related cataracts.

Authors:  Mélanie Lemire; Myriam Fillion; Benoît Frenette; Annie Mayer; Aline Philibert; Carlos José Sousa Passos; Jean Rémy Davée Guimarães; Fernando Júnior Barbosa; Donna Mergler
Journal:  Environ Health Perspect       Date:  2010-11       Impact factor: 9.031

Review 10.  The syndrome of inherited partial SBP2 deficiency in humans.

Authors:  Alexandra M Dumitrescu; Caterina Di Cosmo; Xiao-Hui Liao; Roy E Weiss; Samuel Refetoff
Journal:  Antioxid Redox Signal       Date:  2010-04-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.